FUT8
Basic information
Region (hg38): 14:65410592-65744121
Links
Phenotypes
GenCC
Source:
- congenital disorder of glycosylation with defective fucosylation 1 (Moderate), mode of inheritance: AR
- congenital disorder of glycosylation with defective fucosylation 1 (Definitive), mode of inheritance: AR
- congenital disorder of glycosylation with defective fucosylation 1 (Strong), mode of inheritance: AR
- congenital disorder of glycosylation with defective fucosylation 1 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Congenital disorder of glycosylation with defective fucosylation 1 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Craniofacial; Musculoskeletal; Neurologic | 29304374 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (64 variants)
- Inborn_genetic_diseases (64 variants)
- FUT8-related_disorder (16 variants)
- Congenital_disorder_of_glycosylation_with_defective_fucosylation_1 (13 variants)
- not_specified (2 variants)
- See_cases (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the FUT8 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001371533.1. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 34 | 2 | 37 | ||
| missense | 1 | 75 | 3 | 3 | 82 | |
| nonsense | 2 | 2 | 2 | 6 | ||
| start loss | 0 | |||||
| frameshift | 1 | 1 | ||||
| splice donor/acceptor (+/-2bp) | 1 | 1 | ||||
| Total | 3 | 3 | 79 | 37 | 5 |
Highest pathogenic variant AF is 0.0000054735738
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| FUT8 | protein_coding | protein_coding | ENST00000360689 | 9 | 333530 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 125726 | 0 | 21 | 125747 | 0.0000835 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 2.20 | 206 | 316 | 0.652 | 0.0000171 | 3760 |
| Missense in Polyphen | 60 | 133.22 | 0.45037 | 1573 | ||
| Synonymous | -1.79 | 131 | 107 | 1.22 | 0.00000525 | 1093 |
| Loss of Function | 3.75 | 10 | 33.3 | 0.300 | 0.00000215 | 346 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000148 | 0.000148 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000109 | 0.000109 |
| Finnish | 0.000139 | 0.000139 |
| European (Non-Finnish) | 0.0000705 | 0.0000703 |
| Middle Eastern | 0.000109 | 0.000109 |
| South Asian | 0.0000995 | 0.0000980 |
| Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the addition of fucose in alpha 1-6 linkage to the first GlcNAc residue, next to the peptide chains in N-glycans. {ECO:0000269|PubMed:17172260, ECO:0000269|PubMed:9133635}.;
- Pathway
- N-Glycan biosynthesis - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human);Glycosaminoglycan biosynthesis - keratan sulfate - Homo sapiens (human);MECP2 and Associated Rett Syndrome;Post-translational protein modification;Reactions specific to the complex N-glycan synthesis pathway;N-glycan antennae elongation in the medial/trans-Golgi;Metabolism of proteins;Transport to the Golgi and subsequent modification;Asparagine N-linked glycosylation;N-Glycan biosynthesis
(Consensus)
Recessive Scores
- pRec
- 0.201
Intolerance Scores
- loftool
- 0.298
- rvis_EVS
- -0.47
- rvis_percentile_EVS
- 23.43
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.497
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Zebrafish Information Network
- Gene name
- fut8a
- Affected structure
- retinal ganglion cell
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- in utero embryonic development;protein N-linked glycosylation;N-glycan processing;transforming growth factor beta receptor signaling pathway;integrin-mediated signaling pathway;respiratory gaseous exchange;oligosaccharide biosynthetic process;regulation of gene expression;cell migration;protein N-linked glycosylation via asparagine;protein glycosylation in Golgi;N-glycan fucosylation;L-fucose catabolic process;receptor metabolic process;GDP-L-fucose metabolic process;regulation of cellular response to oxidative stress
- Cellular component
- Golgi membrane;Golgi apparatus;cytosol;membrane;integral component of membrane;Golgi cisterna membrane;extracellular exosome
- Molecular function
- glycoprotein 6-alpha-L-fucosyltransferase activity;SH3 domain binding;alpha-(1->6)-fucosyltransferase activity